SCHEDULE: Goldman Sachs Discloses 4.1% Stake in Oaktree III Life Sciences
Beneficial Ownership Report
Goldman Sachs Group and its affiliate have reported a 4.1% beneficial ownership stake in Oaktree Acquisition Corp. III Life Sciences.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, collectively hold beneficial ownership of 803,487 Class A ordinary shares in Oaktree Acquisition Corp. III Life Sciences.
- This ownership represents 4.1% of the issuer's Class A ordinary shares.
- Both entities share voting and dispositive power over all 803,487 shares, with no sole voting or dispositive power reported.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, not a performance report, thus sentiment is neutral.
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's operations or financial performance.
Industry Context
This filing indicates a significant institutional investment by Goldman Sachs in a life sciences-focused Special Purpose Acquisition Company (SPAC), reflecting continued interest from major financial institutions in the life sciences sector and SPAC vehicles.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact | Multiple individuals (Papa Lette, Akash Keshari, Regina Chan, Andrzej Szyszka, Ameen Soetan, Rahail Patel, Santosh Vinayagamoorthy, Sadhiya Raffique, Matthew Pomfret, Abhishek Vishwanathan, Mariana Audeves, Veronica Mupazviriwo, Elizabeth Novak, Sam Prashanth) | Multiple individuals (Sadhiya Raffique, Santosh Vinayagamoorthy, D Guru Prasad, Tobi Amusan, Akash Keshari, Papa Lette, Andrzej Szyszka, Rahail Patel, Taiki Misu, Regina Chan, Mariana Audeves Martinez, Asheesh Bajaj, Abhilasha Bareja, Veronica Mupazviriwo, Sam Prashanth, Ameen Soetan, Abhishek Vishwanathan, Elizabeth Novak, Matthew Pomfret) | July 16, 2025 | Supersession of previous Power of Attorney documents for The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, updating the list of authorized attorneys-in-fact for SEC filings. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have issued new Powers of Attorney, superseding previous ones dated July 29, 2024, and October 1, 2024, respectively. These new powers authorize specific individuals to execute SEC filings on their behalf. | July 16, 2025 | This is an internal governance update for Goldman Sachs, streamlining the authorization process for SEC filings. It does not directly impact the corporate governance of Oaktree Acquisition Corp. III Life Sciences. |
Stakeholder Impact
- Shareholders of Oaktree Acquisition Corp. III Life Sciences may view Goldman Sachs' 4.1% stake as a positive signal of institutional confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| July 29, 2024 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. was superseded. |
| October 1, 2024 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC was superseded. |
| June 30, 2025 | Date of the event which required the filing of this Schedule 13G statement. |
| July 16, 2025 | Effective date of the new Power of Attorney granted by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. |
| August 1, 2025 | Date of filing for this Schedule 13G Amendment No. 1. |
| July 16, 2026 | Expiration date of the current Power of Attorney for The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. |
Keywords
Goldman Sachs, Oaktree Acquisition Corp. III Life Sciences, Schedule 13G, Beneficial Ownership, Investment, Class A ordinary shares, Financial Services, Life Sciences SPAC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.